雾化吸入重组人干扰素α1b治疗小儿毛细支气管炎的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 雾化吸入重组人干扰素α1b治疗小儿毛细支气管炎的临床观察
TITLE:
摘要: 目的:观察雾化吸入重组人干扰素α1b治疗小儿毛细支气管炎的疗效和安全性。方法:60例毛细支气管炎患儿随机均分为低剂量组、高剂量组和对照组。各组患儿均给予吸痰、化痰、抗感染等常规对症治疗。在此基础上,低剂量组患儿给予重组人干扰素α1b 1~2 μg/(kg·次),加入0.9%氯化钠注射液3 ml中,压缩雾化吸入,每日2次;高剂量组患儿给予重组人干扰素α1b 3~4 μg/(kg·次),加入0.9%氯化钠注射液3 ml中,压缩雾化吸入,每日2次;对照组患儿给予病毒唑10~15 mg/(kg·d),按1 ∶ 1的比例加入5%葡萄糖注射液中,静脉滴注,每日1次。各组疗程均为5~7 d。观察各组患儿的临床疗效,咳嗽消失时间、喘息消失时间、肺部啰音消失时间、三凹征消失时间、住院时间及不良反应发生情况。结果:高剂量组患儿咳嗽消失时间、喘息消失时间、肺部啰音消失时间、三凹征消失时间、住院时间均显著短于低剂量组,而低剂量组短于对照组,差异均有统计学意义(P<0.05)。高剂量组患儿总有效率显著高于低剂量组,而低剂量组高于对照组,差异均有统计学意义(P<0.05)。各组患儿治疗期间均未见明显不良反应发生。结论:在常规治疗的基础上,雾化吸入重组人干扰素αlb治疗小儿毛细支气管炎疗效和安全性均较好。
ABSTRACT: OBJECTIVE:To observe the efficacy and safety of aerosol inhalation recombinant human interferon α1b in the treatment of bronchiolitis in children. METHODS: 60 children with bronchiolitis were randomly divided into low-dose group, high-dose group and control group. All children were given tracheal suctioning, phlegm dispersing and other symptomatic treatment. Based on it, low-dose group was given recombinant human interferon α1b 1-2 μg/(kg·times), adding into 3 ml 0.9% Sodium chloride injection, compression aerosol inhalation, twice a day; high-dose group was given recombinant human interferon α1b 3-4 μg/(kg·times), adding into 3 ml 0.9% Sodium chloride injection, compression aerosol inhalation, twice a day; control group was given ribavirin 10-15 mg/(kg·d), adding into 5% Glucose injection at ratio of 1 ∶ 1 by intravenous infusion, once a day. The treatment course for all groups was 5-7 d. Clinical efficacy, disappearance time of cough, respite, rale and three depressions, hospitalization time and incidence of adverse reactions in all groups were observed. RESULTS: Disappearance time of cough, respite, rale and three depressions and hospitalization time in high-dose group were significantly shorter than low-dose group and low-dose group shorter than control group, the differences were statistically significant (P<0.05). Total effective rate in high-dose group was significantly higher than low-dose group and low-dose group higher than control group, the differences were statistically significant (P<0.05). There were no obvious adverse reactions during treatment. CONCLUSIONS: Based on conventional treatment, both efficacy and safety of aerosol inhalation recombinant human interferon α1b in the treatment of bronchiolitis in children are good.
期刊: 2016年第27卷第6期
作者: 康利娜,成芳,安红,董英
AUTHORS: KANG Li’na,CHENG Fang,AN Hong,DONG Ying
关键字: 雾化吸入; 重组人干扰素α1b ;毛细支气管炎 ;疗效;安全性
KEYWORDS: Aerosol inhalation; Recombinant human interferon α1b; Bronchiolitis; Efficacy; Safety
阅读数: 469 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!